The effects of insulin and liraglutide on osteoprotegerin and vascular calcification in vitro and in patients with type 2 diabetes

European Journal of Endocrinology

Volumn 173, Issue 1, 2015, Pages 53-61

  Davenport, Colin ^a   Mahmood, Wan A ^b   Forde, Hannah ^a   Ashley, David T ^a   Agha, Amar ^a   McDermott, John ^b   Sreenan, Seamus ^b   Thompson, Christopher J ^a   McGrath, Frank ^a   McAdam, Brendan ^a   Cummins, Philip M ^c   Smith, Diarmuid ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b Stroke and Hypertension Unit   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RUNX2; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON LIKE PEPTIDE 1; LONG ACTING INSULIN; METFORMIN; RUNX2 PROTEIN, HUMAN; SIALOGLYCOPROTEIN;

ADULT; ALP GENE; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY MASS; BONE DEVELOPMENT; BSP GENE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOGENIC GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SECRETION; PROTEIN SYNTHESIS; RUNX2 GENE; AGED; ANALOGS AND DERIVATIVES; BIOASSAY; BIOSYNTHESIS; BLOOD; CELL CULTURE; CHEMICALLY INDUCED; COMPLICATION; CORONARY BLOOD VESSEL; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; PATHOLOGY; PILOT STUDY; VASCULAR SMOOTH MUSCLE;

AGED; ALKALINE PHOSPHATASE; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; ENDPOINT DETERMINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; IN VITRO TECHNIQUES; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; OSTEOPROTEGERIN; PILOT PROJECTS; PROSPECTIVE STUDIES; SIALOGLYCOPROTEINS; VASCULAR CALCIFICATION;

EID: 84935122687     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-1137     Document Type: Article

References (23)

1. Johnson RC, Leopold JA & Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circulation Research 2006 99 1044-1059. (doi:10.1161/01.RES.0000249379.55535.21)
2. Abedin M, Tintut Y & Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 1161-1170. (doi:10.1161/01.ATV.0000133194.94939.42)
3. Schurgin S, Rich S & Mazzone T. Increased prevalence of significant coronary artery calcification in patients with diabetes. Diabetes Care 2001 24 335-338. (doi:10.2337/diacare.24.2.335)
4. Chen NX & Moe SM. Vascular calcification: pathophysiology and risk factors. Current Hypertension Reports 2012 14 228-237. (doi:10.1007/s11906-012-0265-8)
5. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 1260-1268. (doi:10.1101/gad.12.9.1260)
6. Tintut Y & Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. Journal of Investigative Medicine 2006 54 395-401. (doi:10.2310/6650.2006.06019)
7. Jorgensen GM, Vind B, Nybo M, Rasmussen LM & Hojlund K. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity. European Journal of Endocrinology 2009 161 95-101. (doi:10.1530/EJE-09-0141)
8. Nuche-Berenguer B, Moreno P, Esbrit P, Dapía S, Caeiro JR, Cancelas J, Haro-Mora JJ & Villanueva-Peñacarrillo ML. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states. Calcified Tissue International 2009 84 453-461. (doi:10.1007/s00223-009-9220-3)
9. Olesen P, Nguyen K, Wogensen L, Ledet T & Rasmussen LM. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. American Journal of Physiology. Heart and Circulatory Physiology 2007 292 H1058-H1064. (doi:10.1152/ajpheart.00047.2006)
10. Yuan LQ, Zhu JH, Wang HW, Liang QH, Xie H, Wu XP, Zhou H, Cui RR, Sheng ZF, Zhou HD et al. RANKL is a downstream mediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells. PLoS ONE 2011 6 e29037. (doi:10.1371/journal.pone.0029037)
11. Pun KK, Lau P & Ho PW. The characterization, regulation, and function of insulin receptors on osteoblast-like clonal osteosarcoma cell line. Journal of Bone and Mineral Research 1989 4 853-862. (doi:10.1002/jbmr.5650040610)
12. Wang CC, Sorribas V, Sharma G, Levi M & Draznin B. Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. Atherosclerosis 2007 195 e65-e75. (doi:10.1016/j.atherosclerosis.2007.02.032)
13. Costa CH, Batista MC, Moises VA, Kohlmann NB, Ribeiro AB & Zanella MT. Serum insulin levels, 24-hour blood pressure profile, and left ventricular mass in nonobese hypertensive patients. Hypertension 1995 26 1085-1088. (doi:10.1161/01.HYP.26.6.1085)
14. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L & LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009 374 39-47. (doi:10.1016/S0140-6736(09)60659-0)
15. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr & Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology 1990 15 827-832. (doi:10.1016/0735-1097(90)90282-T)
16. Xiang GD, Sun HL & Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Research and Clinical Practice 2007 76 199-206. (doi:10.1016/j.diabres.2006.09.008)
17. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ & Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008 117 411-420. (doi:10.1161/CIRCULATIONAHA.107.707380)
18. Price PA, June HH, Buckley JR & Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1610-1616. (doi:10.1161/hq1001.097102)
19. Ndip A, Wilkinson FL, Jude EB, Boulton AJ & Alexander MY. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. Diabetologia 2014 57 2251-2260. (doi:10.1007/s00125-014-3348-z)
20. Demer LL & Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008 117 2938-2948. (doi:10.1161/CIRCULATIONAHA.107.743161)
21. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine 2012 367 319-328. (doi:10.1056/NEJMoa1203858)
22. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T & Becker RH. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 2012 35 2626-2630. (doi:10.2337/dc12-0270)
23. Cozzolino M, Gallieni M & Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. International Journal of Artificial Organs 2008 31 1002-1003.